What is Fibrocell ?

Fibrocell is a biotechnology company that specializes in the development of autologous cell and gene therapies for skin and connective tissue disorders. The company’s most advanced product candidate is azficel-T, an autologous cell therapy for the treatment of vocal cord scarring, which is also known as vocal cord dysfunction or VCD.

Azficel-T is made from a patient’s own fibroblasts, which are cells that produce collagen and other extracellular matrix components that make up the skin and other connective tissues. The therapy is created by taking a small sample of the patient’s skin, which is then used to grow fibroblasts in a laboratory. These cells are then re-injected into the patient’s vocal cords in order to improve the function of the vocal cords and reduce the symptoms of VCD.

Fibrocell’s product pipeline also includes FCX-007, an investigational gene therapy for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic disorder characterized by severe skin fragility and recurrent blistering.

Fibrocell has also developed a proprietary technology platform, Fibro-X, that allows for the isolation of specific cell types from a patient’s skin for use in gene therapy.

Fibrocell is currently in the clinical trial stage for these product candidates. However, these treatments are not yet approved by the FDA, and safety and efficacy of these treatments have not been established yet.

In conclusion, Fibrocell is a biotechnology company that specializes in the development of autologous cell and gene therapies for skin and connective tissue disorders. The company’s most advanced product candidate is azficel-T, an autologous cell therapy for the treatment of vocal cord scarring. Fibrocell also has several other product candidates in its pipeline, including a gene therapy for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). However, these treatments are not yet approved by the FDA and safety and efficacy of these treatments have not been established yet.